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Background
Cancer is the second leading cause of death in 
Russia [1]. While information on incidence reflects 
the causes of cancer, data for mortality capture 
combined information on relative success of pri-
mary and secondary prevention as well as on cancer 
management. Such data can be applied to illustrate 
societal burden, including economic impact. This 
latter can be separated into two components, 
namely direct healthcare expenses and indirect 
costs associated with lost contribution to the econ-
omy due to absence from work, known as lost pro-
ductivity. Though often dismissed, lost productivity 
through premature cancer mortality of the working 
population may exceed treatment expenses and 
contribute substantially to the overall cost of cancer 
to societies [2].
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productivity losses related to premature cancer 
mortality have been assessed for most developed 
countries [3–10]. however, large-scale assessment of 
productivity losses has never been conducted in 
Russia and given recent efforts of the ministry of 
healthcare to implement cancer control strategies, 
such information is very necessary to guide design of 
national cancer control plans [11].
Aims
The aim of this study was to quantify this aspect of 
cancer burden by estimating years of life lost (yll) 
and thereby calculate productivity losses due to pre-
mature cancer mortality in Russia in 2001–2015 and 
project this up to 2030.
Methods
General approach
We measured the yll and the societal burden of 
cancer in Russia by assessing the impact of prema-
ture cancer mortality on productivity losses. Overall, 
yll were calculated for six calendar periods (2001–
2005, 2006–2010, …, and 2026–2030) by sex and 18 
age groups for the following cancer sites, classified 
using ICD-10 (the International Statistical 
Classification of Diseases and Related health 
problems): lip, oral cavity and pharynx (C00–14), 
oesophagus (C15), stomach (C16), colorectum 
(C18–21), liver (C22), pancreas (C25), larynx (C32), 
trachea and lung (C33–34), bone (C40), skin (mela-
noma) (C43), soft tissues (C46.1,3,7–9,47,49), 
female breast (C50), cervix uteri (C53), corpus uteri 
(C54), ovaries (C56), prostate (C61), kidney (C64), 
bladder (C67), brain and central nervous system 
(C70–72, CnS), hematopoietic and lymphoid malig-
nancies (C81–96) and all cancers combined includ-
ing non-melanoma skin cancers (C00–96). The 
‘other’ category included both cancer sites not men-
tioned earlier and unspecified cancer deaths. This 
was calculated as the difference between the number 
of all cancer deaths combined and the number of 
deaths from cancer-specific sites mentioned above. 
To estimate productivity losses due to cancer-related 
premature mortality in Russia in the period between 
2001 and 2015 and projected until 2030 we applied 
an incidence-based method using the human capital 
approach (hCA).
Cancer mortality and population data
Age- and sex-specific cancer mortality data 
between 2001 and 2015 were acquired from the 
State Cancer Registry (SCR) based in the herzen 
Research Institute of Oncology in moscow [12]. A 
system of obligatory registration and lifetime fol-
low-up of cancer patients was established in the 
uSSR in 1953. mortality data are collected by civil 
registration services and aggregated by the Federal 
State Statistics Service (FSSS). population data, 
based on population censuses of 1989, 2002, 2010 
and average population projections until 2031 
were retrieved from the FSSS [13]. Age-
standardized rates (ASRs) of cancer incidence and 
mortality per 100,000 person-years were calcu-
lated using the modified world standard popula-
tion proposed by Segi [14]. In order to estimate 
trends over time log-transformed ASRs were cal-
culated. To predict cancer mortality rates, we 
applied the norpred prediction tool with a linear 
trend [15]. We derived age-specific yll for each 
5-year period calculated as a function of cancer 
deaths and life expectancy. Cause-deleted life-
tables by period were generated based on data 
from the human mortality Database and forecasts 
with a functional demographic model [16, 17]. 
methods and limitation of the analysis for data 
from the SCR were previously described [18].
All estimations were performed in open-source 
statistical software R (version 3.3.3, 2017-03-06)), 
using packages «nordpred» (accessed on 15 may 
2016)[19] and «demography» (version 1.18) [20].
Economic data
The age- and sex-specific economic data were 
obtained from the FSSS: (a) labour-force participa-
tion rates (2001–2014); (b) averaged annual earnings 
(biennial, between 2002 and 2014); and (c) inflation 
rates (2001–2016). These data also included infor-
mation on retirement and labour-force participation 
after retirement age (official retirement ages are 60 
for men and 55 for women). earnings were converted 
from Russian rubles to 2016 uS dollars after adjust-
ment for inflation based on yearly average currency 
exchange rates. We applied natural splines to interpo-
late employment rate integral and mean wages in 
2001 and 2015, and also to project employment 
rates. For sensitivity analysis, wage growth was esti-
mated based on two gross domestic product (gDp) 
scenarios: (a) gDp growth for 2016, 0.3%; 2018, 
2.7%; 2022, 3.9%; 2024, 4.3%; 2027, 4.1%; 2030, 
4%; and 2035, 3.8%, were used for base-case calcu-
lations, and (b) where gDp growth for 2016, 0.3%; 
2018, 2.0%; 2022, 2.4%; 2024, 2.4%; 2027, 2.2%; 
2030, 1.9%; and 2035, 1.7%, were used for sensitiv-
ity analysis.
Average age-specific wages weighted by age-spe-
cific labour force participation were then calculated. 
An annual discount rate of 2.5% was also applied for 
484  Barchuk et al.
base-case calculations [21]. For sensitivity analysis, 
we additionally applied discount rates of 0% and 5%. 
gDp based on purchasing power parity in 2011 
international uS dollars was acquired from the World 
Bank Database along with a deflator in order to 
transform the gpD to 2016 uS dollars. In the base-
case calculations, any earnings from work force par-
ticipation were discontinued at the age of 70 as 
currently reported by FSSS. however, in the sensi-
tivity analysis we also explored additional scenarios: 
where earnings were discontinued at an earlier age 
(65 and 55) and where earnings were not discontin-
ued but projected to allow workforce participation 
until the end of life.
Estimation of lost productivity
The hCA assumes that economic output of an indi-
vidual equates to wage rate, so that premature death, 
by cutting short the working life, produces economic 
losses to society equal to the lost earnings. To calculate 
productivity losses, we used age- and period-specific 
death and economic data. All results were expressed in 
2016 uS dollars. First (2001–2005), most recent 
(2011–2015) and last projected (2026–2030) periods 
for the base-case scenario were reported in Table I.
Ethical approval
This study utilized publicly available secondary 
aggregate data, and thus did not require, according 
to the current legislature, ethical approval.
Results
Trends in age-standardized mortality rates per 
100,000 and YLL from cancer
mortality for most cancer types was going down dur-
ing the study period (Figure 1; Supplementary mate-
rial Table S1). There was an upward trend between 
2001 and 2015 for melanoma, pancreas, brain and 
CnS cancer mortality in both men and women, for 
lip, oral and pharynx, larynx and cervix uteri cancer 
mortality in women, and for prostate cancer mortal-
ity in men. Overall yll increased for most cancer 
sites, except larynx in men, and stomach and bone in 
both men and women. The overall annual yll due 
to premature cancer mortality in men increased from 
11 million years in 2001–2005 to 12 million years in 
2011–2015. It was predicted to further increase to 14 
million years in 2026–2030.
Taking into account both relative and absolute 
changes in the overall yll between 2001 and 2015, 
cervix uteri, pancreas and colorectal cancer showed 
the largest increases. lip, oral and pharynx cancer 
showed the largest relative change, while cervix uteri 
cancer exhibited the largest absolute growth in 
women. prostate cancer showed the highest absolute 
and relative increase in yll in men, with major 
increases also in lip, oral and pharynx, colorectal and 
pancreas cancer in men in both relative and absolute 
terms (Supplementary material Figure S1).
Overall productivity losses and losses per one 
death
Annual productivity losses due to cancer mortality in 
Russia for the reported cancer types are presented in 
Table I. The annual overall productivity losses due to 
cancer mortality were reaching a peak of uS$8.3b in 
2006–2010 (uS$3.2b in women and uS$5.1b in 
men) (Figure 2).
productivity losses per cancer death were higher in 
men (Table I). yet, productivity losses per cancer death 
in women are predicted to grow faster than in men, 
from uD$18,622 in 2001–2005 to uS$22,386 in 
2026–2030. productivity losses per cancer death were 
highest for bone, brain and CnS, cervix uteri, soft tis-
sues cancer hematopoietic and lymphoid malignancies 
and melanoma of the skin (Supplementary material 
Figure S2).
In total, the estimated productivity losses decreased 
from 0.28% of gDp in 2001–2005 to 0.24% in 
2011–2015 and are predicted to further decrease to 
0.14% in 2026–2030. While this decline was seen for 
most cancer sites increases were found for lip, oral 
and pharyngeal, pancreatic, lung, cervix uteri in 
women; prostate in men; and oesophagus cancer in 
men and women.
Productivity losses by cancer type
Annual overall productivity losses were highest for 
breast cancer in women (uS$0.6b or 20% of all 
losses in 2011–2015) and lung cancer in men ($1.2b 
or 24% in 2011–2015), which remain the highest-
ranking cancers in the next two decades of the study 
period (Figure 2).
Relative change in productivity losses between 
2011–2015 and 2026–2030 in women was highest 
for the larynx (174%), lip, oral and pharynx (152%), 
oesophagus (136%) and cervix uteri cancer (111%). 
During the same period, the absolute predicted 
change was highest for cervix uteri (+ uS$214m) 
and lung cancer (+ uS$61m) in women (Figure 3). 
In men, the relative change was highest for prostate 
cancer (111%), lip, oral and pharyngeal cancer 
(82%), oesophagus (64%), and liver cancer (69%), 
while the largest absolute increase was noted for lip, 
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oral and pharyngeal (+ uS$182m) and colorectal 
cancer (+ uS$103m) (Figure 3).
Sensitivity analyses
Changing the discount rate affected the overall 
amount of annual productivity losses but did not 
affect the relative distribution of losses by cancer 
types (Supplementary material Figures S3 and S4). 
Cutting the earnings at a certain age decreased the 
amount of productivity losses. In the scenario, where 
earlier age at earnings was discontinued, more pro-
ductivity losses were assigned to cancer types affect-
ing younger age groups (e.g. cervix uteri) and less 
productivity losses to those with deaths at older age 
groups (e.g. prostate) (Supplementary material 
Figures S5–S7). however, the major findings 
reported for the base-case scenario remained. The 
maximum overall annual productivity losses for 
2011–2015 were reached without discontinuation of 
earnings with 0% discount and the base-case gDp 
growth scenario – uS$4.03b in women and 
uS$6.04b in men – while the lowest figures were 
obtained with discontinuation at the age 55 with a 
5% discount and the second gDp growth scenario 
– uS$1.52b in women and uS$2.11b in men 
(Supplementary material Figures S9–S10).
Discussion
To our knowledge, this is the first analysis of trends 
and prediction of cancer mortality related productiv-
ity costs in Russia. A large overall cost of cancer death 
in Russia was found amounting to uS$8.1b or 0.24% 
of gDp in 2011–2015. It is expected to remain high 
in 2030 (uS$7.5b or 0.14% of gDp). The result also 
provides a wide perspective of major contributors to 
these losses, the greatest cause being lung cancer 
(uS$1.2b or 24% of the total loss) in men and breast 
cancer (uS$0.6b or 20%) in women in 2011–2015. 
Quantitative assessment of the rising losses linked to 
cancers known to be related to human papilloma 
virus (hpv) infection, revealed a figure for cervical 
cancer in women of uS$233m in 2001, which is 
expected to almost double to uS$447m in 2030. This 
study provides an economic appraisal for the Russian 
government to set priorities in cancer control activi-
ties, including primary prevention (e.g. tobacco con-
trol or hpv control) and population-based cancer 
screening (cervical, breast and colorectal).
Figure 1. Age-standardized mortality rates per 100,000 (presented on a semi-log scale) according to cancer types and sex between 2001 
and 2030 in Russia (dash–dot line separates recent and future predicted rates).
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Our findings can be compared with reports from 
other countries, which give similar relative estimates 
when costs are compared to gDp, taking into account 
differences in mortality and population size. In 
europe, productivity losses due to cancer mortality 
in 2008 were 0.36% of total gDp ranging between 
0.15 and 0.67% by country [22]. In the uSA, pro-
ductivity losses were higher: about 1.11% of gDp 
based on the 2000 estimates [3]. Cancer mortality 
related productivity costs in BRICS countries in 
2008 were estimated as 0.21% gDp for Brazil, 
0.25% for Russia, 0.34% gDp for China, 0.36% 
gDp for India and 0.49% for South Africa. Our 
results were consistent with these findings. [10].
We estimated an annual loss of uS$8.1b due to 
premature deaths from cancer in Russia in 2011–
2015. extrapolating this estimate to total costs of can-
cer in Russia without high-quality data for direct 
medical costs related to cancers remains challenging. 
In a recent systematic review the proportion of cancer 
mortality related productivity losses was reported to 
be over 50% of the total cost [7]. however, in a large 
european study this proportion ranged from 24 to 
54% for 27 countries [22, 23]. With some uncertainty, 
overall cancer costs in Russia can be estimated to be at 
least uS$15b but probably more than uS$20b per 
year based on extrapolation from our findings.
Productivity losses by cancer type
In general, we have observed a decline in the mortality 
from cancers in Russia with ASRs dropping between 
2001 and 2015 from 94 to 87 per 100,000 in women 
(7%) and from 190 to 167 per 100,000 in men (12%), 
which reflected a decrease in the burden of cancer to 
the gDp from 0.27 to 0.24%. Some of this decrease 
can be related to the decline in smoking-related can-
cers in Russia as much of the productivity losses, par-
ticularly among men, are driven by smoking-related 
cancers such as lung cancer (24% of the total produc-
tivity loss in 2011–2015). The Russian Federation has 
been a party to the WhO Framework Convention on 
Tobacco Control since 2008 and Federal law on 
health protection from exposure to environmental 
Tobacco Smoke and the Consequences of Tobacco 
Consumption was adopted in 2013 – actions that 
Figure 2. Overall observed and predicted average annual productivity losses due to premature cancer mortality in Russia in 2001–2030 and 
ranking according to cancer sites and sex.
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clearly will contribute to further mortality decline. yet, 
the smoking prevalence remains high among men in 
Russia (daily smoking for 51% of men in 2015) [24]. 
unlike many reports in other european countries, 
costs associated with women lung cancer deaths were 
moderate, ranking eighth of all costs in women prob-
ably related to a relatively low daily smoking preva-
lence (i.e. 15% in 2015) [24]. A slight increase in rates 
of lung cancer has been observed in women and con-
tinued increase in lung-cancer rates reported in other 
countries caution for a similar rise in Russia. 
Considering these factors, additional smoking cessa-
tion counselling might be implemented as part of 
screening programmes [25].
On the other hand, we saw a substantial increase in 
the contribution of hpv-related cancers (cervix uteri, 
oral and pharynx) to future productivity losses in 
Russia. At the moment, hpv vaccination is not avail-
able as a nationwide programme and cervical cancer 
screening remains opportunistic for a select propor-
tion of the population [26]. Rising productivity losses 
from oral and pharynx cancers in both sexes adds 
additional motivation to put forward population-
based hpv control activities at the national level.
We also saw a rapid rise in productivity losses from 
oesophagus, liver and pancreas cancer mortality, all 
traditionally related to smoking and alcohol consump-
tion, that can also be partly explained by the increas-
ing obesity prevalence in Russia and other lifestyle risk 
factors [27]. In addition, growing incidence and sub-
stantial losses from colorectal cancer mortality as well 
as a large contribution of breast cancer to the eco-
nomic cost underline the need to assess the major risk 
factors for these cancers and also the effectiveness of 
early detection and management in order to adapt 
existing national control policies.
A few limitations of the study should be noted. 
Quality of the data used in the analysis may affect 
the result, and as such the data input for this study 
needs to be considered when interpreting reported 
results. The ‘other cancer types’ category in our 
analysis consisted of two groups: the first including 
unspecified tumors (C76–C80) with around 4% out 
of the total reported deaths. The second group is 
other specific cancer types (around 3%), for which 
data were not available for the whole study period. 
The hCA is only one of several approaches to esti-
mate societal burden of cancer. The friction cost 
approach (FCA) is an alternative. As such, losses 
based on the hCA calculations are considerably 
higher than calculated by FCA [28]. yet, the hCA 
has become widely used and the methodology has 
Figure 3. Change in in annual productivity losses due to premature cancer mortality in Russia between 2001–2005 and 2026–2030 accord-
ing to cancer type and sex.
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become a standard to estimate productivity losses 
for calculating indirect non-medical costs due to 
mortality [23, 29]. This analysis includes only paid 
productivity losses, so other indirect and direct 
losses, like unpaid work such as caring for children 
or sick relatives, and volunteering work, as well as 
other payments, are not included. Additionally, our 
method does not consider productivity losses that 
occur due to illness and disability, and hence loss of 
income, related to cancer. estimating individual 
losses is an optimal approach but it is rarely feasible 
and renders such results incomparable to other stud-
ies due to differences in data collection and availabil-
ity [30]. Furthermore, projected losses need to be 
carefully interpreted due to uncertainty in the eco-
nomic, population and cancer predictions.
The primary strength of our study is that we 
provide comprehensive analysis of the trends and 
changes in productivity losses over time while most 
similar studies report cross-sectional findings. That 
allowed us to capture how the changing cancer 
burden is affecting economic losses in Russia. We 
used combined economic and epidemiological 
data available for the whole period of the study. In 
the absence of the reliable individual-level data, 
results of our and similar studies must be used to 
approximate the overall cancer costs in Russia, but 
future research would benefit from having more 
detailed data to estimate the economic burden of 
cancer in Russia.
conclusions
productivity losses due to premature cancer mortality 
in Russia are substantial and amount to uS$8b per 
year. The losses are expected to drop from 0.28% of 
gDp in 2001 to 0.14% in 2030 mostly due to a 
decline in the mortality from cancers in Russia. While 
the losses are highest for breast cancer in women and 
lung cancer in men, the relative growth in productivity 
losses was highest for hpv-related cancer mortality.
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